Pierre Axel Vinot | Director, CMC Portfolio Management
SparingVision

Pierre-Axel Vinot brings over 10 years of experience in preclinical research, clinical trials, and CMC management, particularly in the field of cell and gene therapies. He holds a Pharm.D. from the University of Paris and a Ph.D. from Sorbonne University and completed a specialized residency in biotech product development within AP-HP, the Europe’s largest hospital group. His career spans academic research, public hospitals, and biotech companies, where he has worked on advancing innovative therapies. Currently, Dr. Vinot leads the CMC portfolio at SparingVision, focusing on the development and manufacturing of gene therapy solutions for retinal degeneration.